Advaxis, Inc.
Records under this name other than the patents Advaxis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,499,602 | Non-Hemolytic Llo Fusion Proteins and Methods of Utilizing Same Formerly held In force · High confidence | In force | High confidence | |
| US 10,189,885 | Non-Hemolytic Llo Fusion Proteins and Methods of Utilizing Same Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,012,141 | Compositions and methods comprising KLK3 of FOLH1 antigen Formerly held In force · High confidence | In force | High confidence | |
| US 9,650,639 | Dual delivery system for heterologous antigens Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,644,212 | Dual delivery system for heterologous antigens Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,064,898 | Listeria-Based Adjuvants Formerly held In force · Low confidence | In force | Low confidence | |
| US 9,463,227 | Listeria-Based Adjuvants Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,017,660 | Compositions and Methods for Prevention of Escape Mutation in the Treatment of HER2/NEU Over-Expressing Tumors Formerly held In force · High confidence | In force | High confidence | |
| US 9,084,747 | Compositions and Methods for Prevention of Escape Mutation in the Treatment of HER2/NEU Over-Expressing Tumors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,058,599 | Suppressor cell function inhibition following Listeria vaccine treatment Formerly held In force · From the USPTO record | In force | From the USPTO record |